Salem Ahmed Ebada, Fine Gabriel C, Covington Matthew F, Koppula Bhasker R, Wiggins Richard H, Hoffman John M, Morton Kathryn A
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
Department of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.
Cancers (Basel). 2022 Jun 18;14(12):3000. doi: 10.3390/cancers14123000.
Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. The advent of new FDA-approved radiopharmaceuticals for prostate cancer imaging has revolutionized PET-CT imaging in this important disease, and these are addressed in this report. However, [F]F-fluoro-2-deoxy-d-glucose (FDG) remains the mainstay for PET-CT imaging of gynecologic and many other genitourinary malignancies. This information will serve as a guide for the appropriate role of PET-CT in the clinical management of gynecologic and genitourinary cancer patients for health care professionals caring for adult cancer patients. It also addresses the nuances and provides guidance in the accurate interpretation of FDG PET-CT in gynecological and genitourinary malignancies for imaging providers, including radiologists, nuclear medicine physicians and their trainees.
同时进行的正电子发射断层扫描和计算机断层扫描（PET-CT）是一种先进的成像方式，在肿瘤学中有多种应用，包括分期、治疗评估、再分期和纵向监测。这一系列六篇综述文章旨在为医疗服务提供者和影像专业人员提供实用信息，介绍PET-CT在成年患者肿瘤学适应症方面的最佳使用方法和解读策略。在本系列的第四篇文章中，讨论了临床实践中更常见的妇科和成人泌尿生殖系统恶性肿瘤，重点介绍了美国食品药品监督管理局（FDA）批准的和临床可用的放射性药物。用于前列腺癌成像的新型FDA批准放射性药物的出现，彻底改变了这种重要疾病的PET-CT成像，本报告对此进行了阐述。然而，[F]F-氟代脱氧葡萄糖（FDG）仍然是妇科和许多其他泌尿生殖系统恶性肿瘤PET-CT成像的主要药物。这些信息将为医疗保健专业人员在妇科和泌尿生殖系统癌症患者的临床管理中正确使用PET-CT提供指导，这些专业人员负责照顾成年癌症患者。它还阐述了细微差别，并为影像提供者（包括放射科医生、核医学医生及其学员）准确解读妇科和泌尿生殖系统恶性肿瘤的FDG PET-CT提供指导。
